538 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by Center For Asset Management LLC

Center For Asset Management LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 1st quarter, HoldingsChannel.com reports. The firm bought 538 shares of the company’s stock, valued at approximately $226,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Geode Capital Management LLC raised its stake in IDEXX Laboratories by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock worth $948,279,000 after acquiring an additional 37,734 shares in the last quarter. Bamco Inc. NY raised its stake in IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company’s stock worth $829,163,000 after acquiring an additional 82,264 shares in the last quarter. Invesco Ltd. raised its stake in IDEXX Laboratories by 6.8% during the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock worth $479,999,000 after acquiring an additional 74,324 shares in the last quarter. Norges Bank acquired a new position in IDEXX Laboratories during the fourth quarter worth $412,258,000. Finally, GAMMA Investing LLC raised its stake in IDEXX Laboratories by 59,810.7% during the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock worth $3,856,950,000 after acquiring an additional 916,898 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $523.92 on Friday. The stock has a 50-day moving average price of $486.81 and a 200 day moving average price of $447.64. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. The firm has a market cap of $42.13 billion, a price-to-earnings ratio of 48.42, a PEG ratio of 3.80 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted $2.71 earnings per share. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the business’s stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the sale, the director now directly owns 1,801 shares of the company’s stock, valued at approximately $922,724.34. The trade was a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IDXX. Morgan Stanley increased their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research note on Monday, May 5th. Stifel Nicolaus raised their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the company a “hold” rating in a research note on Monday, May 19th. Leerink Partners raised their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the company an “outperform” rating in a research note on Wednesday, June 11th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $546.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.